<DOC>
	<DOCNO>NCT00063726</DOCNO>
	<brief_summary>The purpose study allow patient receive VELCADE™ ( bortezomib ) Injection experience progressive disease ( PD ) receive high-dose dexamethasone M34101-039 study .</brief_summary>
	<brief_title>A Study PS-341 Given Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone M34101-039</brief_title>
	<detailed_description>The rationale Amendment 2 2-fold . First , intend study serve rollover protocol patient experience progressive disease ( PD ) receive comparator treatment , high-dose dexamethasone , MPI Study M34101-039 , thereby ultimately provide patient participate Study M34101-039 require treatment disease access VELCADE™ ( bortezomib ) Injection , formerly know MLN341 , LDP-341 PS-341 .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Inclusion Criteria Patient experience PD , define SWOG+ criterion treatment highdose dexamethasone MPI Study M34101039 , receive alternate antineoplastic therapy . Intolerance highdose dexamethasone therapy administer MPI study M34101039 qualify PD . Patient , investigator 's opinion , willing able comply protocol requirement . Patient give voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw patient time without prejudice future medical care . Female patient postmenopausal , surgically sterilize , willing use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) Screening End Treatment visit . Male patient agree use acceptable barrier method contraception Screening End Treatment visit . Patient meet follow pretreatment laboratory criterion within 14 day Baseline ( Day 1 Cycle 1 , study drug administration ) . ( Note End Treatment assessment MPI study M34101039 may qualify Screening assessment MPI study M34101040 perform within 14 day Baseline visit . ) : Platelet count ≥20 X 10E+9/L , without transfusion support . Hemoglobin ≥7.0 g/dL , without transfusion support . Absolute neutrophil count ( ANC ) ≥0.5 x 10E+9/L , without growth factor support . Serum calcium &lt; 14 mg/dL ( 3.5 mmol/L ) . Aspartate transaminase ( AST ) : ≤2.5 x upper limit normal ( ULN ) . Alanine transaminase ( ALT ) : ≤2.5 x ULN . Total bilirubin : ≤1.5 x ULN . If calculate measure creatinine clearance : ≥20 mL/minute , assessment specify protocol . If calculate measure creatinine clearance &lt; 20 mL/minute . Exclusion Criteria Patient participate M34101039 confirm PD . Dexamethasone intolerance qualify PD . Patient PD dexamethasone arm MPI Study M34101039 , receive alternate antineoplastic therapy . Patient recover dexamethasonerelated toxicity experience MPI Study M34101039 . Patient known human immunodeficiency virus ( HIV ) positive . ( Patients assess investigator risk HIV infection test accordance local regulation . ) Patient know hepatitis B surface antigenpositive know active hepatitis C infection . ( Patients assess investigator risk hepatitis B C infection test accordance local regulation . ) Female patient pregnant breastfeeding . Patient develop new experienced worsen exist illness completion Study M34101039 , investigator 's opinion , may put patient risk participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Relapsed Multiple Myeloma</keyword>
	<keyword>Refractory Multiple Myeloma</keyword>
</DOC>